MONDAY, MARCH 27, 2017

Phase II study starts for intranasal, seasonal influenza vaccine deltaFLU

VIENNA Read More »

NIAID gives 2 grants for development of anthrax immune globulin therapeutic

Emergent BioSolutions announced that it has been awarded two grants from the National Institute of Allergy and Infectious Diseases totaling $3.8 million to support the development of the anthrax immune globulin (AIG) therapeutic product. Read More »

DHS approves BioThrax as a product for homeland security

Emergent BioSolutions announced that the U.S. Department of Homeland Security has granted its application for designation and certification of BioThrax (Anthrax Vaccine Adsorbed) as a Read More »

U.S. includes BioThrax, Anthrax Immune Globulin in PREP Act

Emergent BioSolutions Inc. announced that two medical countermeasures included in its anthrax franchise have been included as covered countermeasures under the Public Readiness and Emergency Preparedness Act. Read More »

U.S. to purchase 14.5 million more doses of BioThrax

Emergent BioSolutions Inc. announced that it has signed a contract with the U.S. Department of Health and Human Services to supply an additional 14.5 million doses of BioThrax for inclusion in the Strategic National Stockpile. Read More »

Emergent BioSolutions signs $29.7 million contract to develop anthrax vaccine

ROCKVILLE, Md. Read More »

HHS says proposal to provide anthrax vaccine 'technically acceptable'

Emergent BioSolutions Inc. announced that the Department of Health and Human Services has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine (rPA) is technically acceptable. Read More »

Emergent BioSolutions gets $24 million to develop anthrax monoclonal antibody

ROCKVILLE, Md. Read More »

Emergent BioSolutions applauds passage, signing of barda legislation

GAITHERSBURG, Md. Read More »

FDA approves Emergent BioSolutions' supplemental biologics license application

Emergent BioSolutions Inc. announced that the U.S. FDA has approved its supplemental biologics license application for Anthrax Vaccine Adsorbed BioThrax, the only FDA-licensed vaccine to prevent disease caused by Bacillus anthracis. Read More »

More than 3 million doses of BioThrax delivered to HHS

Emergent BioSolutions Inc. that it has successfully completed the fourth-quarter 2006 deliveries of more than 3 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the Department of Health and Human Services. Read More »

Emergent BioSolutions' CEO to ring stock exchange's opening bell

GAITHERSBURG, Md. Read More »

Singer shows how 'quick and easy' H1N1 vaccination can be

Read More »

Zadaxin when used with Novartis vaccine raises immunity, SciClone says

BANGALORE, India Read More »

Inhibitex says recruitment begins for staph vaccine study

Pfizer Inc. has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine in healthy adults. Read More »

Poland refuses H1N1 flu vaccines

WARSAW, Poland Read More »

Merck submits Gardasil data for women 27 to 45

NEW YORK Read More »

Foundation reaches milestone in rotavirus vaccine trial

Rotavirus is responsible for the deaths of more than 1,500 infants and children daily, mainly in developing countries. The International Medica Foundation is sponsoring a Phase II clinical trial of its oral rotavirus vaccine, RotaShield. Read More »

Dynavax Technologies names 2 senior executives

Dynavax Technologies Corp. announced Jan. 12 the addition of two new senior executives to direct key commercial and clinical activities prior to the launch of Heplisav, an investigational adult hepatitis B vaccine. Read More »

GlaxoSmithKline's quarterly sales of H1N1 vaccine lower than forecast

LONDON Read More »